Skip to main content

Table 1 Baseline (mean ± standard deviation) and on-treatment clinical and biochemical attributes

From: NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

  overall males females
number 101 61 40
age (years) 55.6 ± 11.9 54.0 ± 10.7 58.0 ± 13.3
days on treatment 83.8 ± 60.6 90.1 ± 67.6 74.5 ± 47.9
percent on statin 69.3 78.7 55.0
plasma lipids and lipoproteins (mmol/L)
   baseline    
cholesterol    
- total 6.57 ± 1.43 6.33 ± 1.54 6.93 ± 1.18
- LDL 4.51 ± 1.40 4.35 ± 1.53 4.72 ± 1.18
- HDL 1.18 ± 0.30 1.15 ± 0.29 1.22 ± 0.31
triglycerides 2.50 ± 2.36 2.63 ± 2.86 2.32 ± 1.33
   on-treatment    
cholesterol    
- total 5.41 ± 1.32 5.10 ± 1.21 5.88 ± 1.35
- LDL 3.35 ± 1.15 3.21 ± 1.11 3.56 ± 1.19
- HDL 1.23 ± 0.45 1.16 ± 0.33 1.33 ± 0.60
triglycerides 2.25 ± 1.91 2.24 ± 2.12 2.25 ± 1.57
  1. abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein;